21. KETOROLAC (TORADOL®) (NEW '20)

Optional Supplemental Protocol

1. PHARMACOLOGY

a) Inhibits synthesis of prostaglandin, which, in turn, reduces pain and inflammation
b) Antipyretic agent
c) Does not affect CNS, peripheral acting analgesic, therefore, it does not possess the same sedative properties as a narcotic

2. PHARMACOKINETICS

a) Onset: Approximately 30 minutes
b) Peak effects: 1-2 hours
c) Half-life: 4-6 hours

3. INDICATIONS

a) Management of moderate to severe acute pain
b) Consider as a first line medication for renal stones/colic
c) Burns - mild to moderate
d) Non-traumatic neuromuscular pain

4. CONTRAINDICATIONS

a) Hypersensitivity to ketorolac, aspirin, and other NSAIDs
b) Current usage of aspirin or NSAIDs within 6 hours
c) Severe headache or head injury
d) Bleeding or clotting disorder
e) Renal disease or transplant
f) Active or history of peptic ulcer disease (PUD), active or recent history of GI bleed, and active or history of GI perforation
g) Pregnancy or breast feeding
h) Suspected ACS
i) Trauma with suspected bleeding
j) Patients who have not yet reached their second birthday

5. ADVERSE EFFECTS

a) Burning or pain at the injection site
b) Rash / itching
c) GI distress
d) Nausea / vomiting

6. DOSAGE

a) Adult: Administer single dose of 15 mg IV only. No repeat doses.
If IV is unavailable: Administer single dose of 30 mg IM. No repeat doses.

b) Pediatric:
(1) Newly born to 2 years of age: Contraindicated
(2) Age 2 to patients who have not reached their 18th birthday: Administer 0.5 mg/kg IV only to a maximum total dose of 15 mg. No repeat doses.
If IV is unavailable: Administer 1 mg/kg IM to a maximum total dose of 30 mg. No repeat doses.